Apr 18, 2017
Novartis gets second CAR-T candidate FDA ‘breakthrough’ tag As the battle between Swiss major Novartis and biotech rival Kite Pharma heats up to be the first to market a CAR-T cancer med, the Big Pharma has been handed its second FDA ‘breakthrough’ tag for its eagerly awaited JULIET trial. This latest label, which c...
Read More...
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Jan 30, 2026
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper